Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Shahaduzzaman, Md ^a   Nash, Kevin ^a,c   Hudson, Charles ^b   Sharif, Masroor ^a   Grimmig, Bethany ^a   Lin, Xiaoyang ^c   Bai, Ge ^c   Liu, Hui ^c   Ugen, Kenneth E ^a,c   Cao, Chuanhai ^c,d   Bickford, Paula C ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; ALPHA SYNUCLEIN ANTIBODY; COPPER ZINC SUPEROXIDE DISMUTASE; PROTEIN ANTIBODY; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; ANTIBODY; GREEN FLUORESCENT PROTEIN;

AMINO TERMINAL SEQUENCE; ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MICROGLIA; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PROTEIN AGGREGATION; PROTEIN EXPRESSION; RAT; STEREOLOGY; SUBSTANTIA NIGRA; VIRUS TITRATION; ADMINISTRATION AND DOSAGE; ANIMAL; ANIMAL BEHAVIOR; DEPENDOPARVOVIRUS; DRUG EFFECTS; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; PHYSIOLOGY; PROCEDURES;

ANIMALIA; RATTUS;

ALPHA-SYNUCLEIN; ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES; BEHAVIOR, ANIMAL; CELL DEATH; DEPENDOVIRUS; DOPAMINERGIC NEURONS; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INJECTIONS, INTRAPERITONEAL; PARKINSON DISEASE; RATS; SUBSTANTIA NIGRA;

EID: 84922758351     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0116841     Document Type: Article

References (56)

1. Kothawala A, Kilpatrick K, Novoa JA, Segatori L (2012) Quantitative analysis of alpha-synuclein solubility in living cells using split GFP complementation. PLoS One 7: e43505. doi: 10.1371/journal.pone. 0043505 PMID: 22927976
2. Lindstrom V, Ihse E, Fagerqvist T, Bergstrom J, Nordstrom E, et al. (2014) Immunotherapy targeting alpha-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders. Immunotherapy 6: 141-153. doi: 10.2217/imt.13.162 PMID: 24491088
3. Fagerqvist T, Lindstrom V, Nordstrom E, Lord A, Tucker SM, et al. (2013) Monoclonal antibodies selective for alpha-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and alpha-synuclein transgenic mice with the disease-causing A30P mutation. J Neurochem 126: 131-144. doi: 10.1111/jnc.12175 PMID: 23363402
4. Mandler M, Valera E, Rockenstein E, Weninger H, Patrick C, et al. (2014) Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials. Acta Neuropathol.
5. Madeo J, Frieri M (2013) Alzheimer's disease and immunotherapy. Aging Dis 4: 210-220. PMID: 23936745
6. Lannfelt L, Relkin NR, Siemers ER (2014) Amyloid-ss-directed immunotherapy for Alzheimer's disease. J Intern Med 275: 284-295. doi: 10.1111/joim.12168 PMID: 24605809
7. Lemere CA, Masliah E (2010) Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 6: 108-119. doi: 10.1038/nrneurol.2009.219 PMID: 20140000
8. Rafii MS (2013) Update on Alzheimer's Disease Therapeutics. Rev Recent Clin Trials.
9. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, et al. (2008) Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372: 216-223. doi: 10.1016/S0140-6736(08)61075-2 PMID: 18640458
10. Boche D, Denham N, Holmes C, Nicoll JA (2010) Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathol 120: 369-384. doi: 10.1007/ s00401-010-0719-5 PMID: 20632020
11. Boche D, Zotova E, Weller RO, Love S, Neal JW, et al. (2008) Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 131: 3299-3310. doi: 10.1093/brain/ awn261 PMID: 18953056
12. Lambracht-Washington D, Rosenberg RN (2013) Advances in the development of vaccines for Alzheimer's disease. Discov Med 15: 319-326. PMID: 23725605
13. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, et al. (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61: 46-54. PMID: 12847155
14. Kristen Marciniuk RT, and Scott Napper (July 2013) Evidence for Prion-like Mechanisms in Several Neurodegenerative Diseases: Potential Implications for Immunotherapy. Clinical and Developmental Immunology.
15. Schneeberger A, Mandler M, Mattner F, SchmidtW(2012) Vaccination for Parkinson's disease. Parkinsonism Relat Disord 18 Suppl 1: S11-13. doi: 10.1016/S1353-8020(11)70006-2 PMID: 22166404
16. Hutter-Saunders JA, Mosley RL, Gendelman HE (2011) Pathways towards an effective immunotherapy for Parkinson's disease. Expert Rev Neurother 11: 1703-1715. doi: 10.1586/ern.11.163 PMID: 22091596
17. Stefanis L (2012) alpha-Synuclein in Parkinson's disease. Cold Spring Harb Perspect Med 2: a009399. doi: 10.1101/cshperspect.a009399 PMID: 22355802
18. Lashuel HA, Overk CR, Oueslati A, Masliah E (2013) The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 14: 38-48. doi: 10.1038/nrn3406 PMID: 23254192
19. Foulds PG, Mitchell JD, Parker A, Turner R, Green G, et al. (2011) Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB J 25: 4127-4137. doi: 10.1096/fj.10-179192 PMID: 21865317
20. McLean PJ, Kawamata H, Ribich S, Hyman BT (2000) Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. J Biol Chem 275: 8812-8816. PMID: 10722726
21. Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, et al. (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 90: 11282-11286. PMID: 8248242
22. Kim TD, Paik SR, Yang CH (2002) Structural and functional implications of C-terminal regions of alphasynuclein. Biochemistry 41: 13782-13790. PMID: 12427041
23. Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, et al. (2011) Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 6: e19338. doi: 10.1371/journal.pone.0019338 PMID: 21559417
24. Vekrellis K, Stefanis L (2012) Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies. Expert Opin Ther Targets 16: 421-432. doi: 10.1517/14728222.2012.674111 PMID: 22480256
25. Narhi L, Wood SJ, Steavenson S, Jiang Y, Wu GM, et al. (1999) Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J Biol Chem 274: 9843-9846. PMID: 10092675
26. Gardai SJ, Mao W, Schule B, Babcock M, Schoebel S, et al. (2013) Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease. PLoS One 8: e71634. doi: 10.1371/journal.pone.0071634 PMID: 24058406
27. Mosley RL, Hutter-Saunders JA, Stone DK, Gendelman HE (2012) Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb Perspect Med 2: a009381. doi: 10.1101/cshperspect. a009381 PMID: 22315722
28. Sanchez-Guajardo V, Barnum CJ, Tansey MG, Romero-Ramos M (2013) Neuroimmunological processes in Parkinson's disease and their relation to alpha-synuclein: microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro 5: 113-139. doi: 10.1042/AN20120066 PMID: 23506036
29. Koehler NK, Stransky E, Shing M, Gaertner S, Meyer M, et al. (2013) Altered serum IgG levels to alphasynuclein in dementia with Lewy bodies and Alzheimer's disease. PLoS One 8: e64649. doi: 10.1371/ journal.pone.0064649 PMID: 23741358
30. Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, et al. (2009) Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119: 182-192. doi: 10.1172/JCI36470 PMID: 19104149
31. Peterson LJ, Flood PM (2012) Oxidative stress and microglial cells in Parkinson's disease. Mediators Inflamm 2012: 401264. doi: 10.1155/2012/401264 PMID: 22544998
32. Bae EJ, Lee HJ, Rockenstein E, Ho DH, Park EB, et al. (2012) Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J Neurosci 32: 13454-13469. PMID: 23015436
33. Tran HT, Chung CH, Iba M, Zhang B, Trojanowski JQ, et al. (2014) alpha-Synuclein Immunotherapy Blocks Uptake and Templated Propagation of Misfolded alpha-Synuclein and Neurodegeneration. Cell Rep 7: 2054-2065. doi: 10.1016/j.celrep.2014.05.033 PMID: 24931606
34. Kosloski LM, Ha DM, Hutter JA, Stone DK, Pichler MR, et al. (2010) Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases. J Neurochem 114: 1261-1276. doi: 10.1111/j.1471-4159.2010.06834.x PMID: 20524958
35. Carty N, Lee D, Dickey C, Ceballos-Diaz C, Jansen-West K, et al. (2010) Convection-enhanced delivery and systemic mannitol increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene product in the adult mouse brain. J Neurosci Methods 194: 144-153. doi: 10.1016/j.jneumeth. 2010.10.010 PMID: 20951738
36. Gorbatyuk OS, Li S, Nash K, Gorbatyuk M, Lewin AS, et al. (2010) In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. Mol Ther 18: 1450-1457. doi: 10.1038/mt.2010.115 PMID: 20551914
37. Anderson NL, Jackson A, Smith D, Hardie D, Borchers C, et al. (2009) SISCAPA peptide enrichment on magnetic beads using an in-line bead trap device. Mol Cell Proteomics 8: 995-1005. doi: 10.1074/ mcp.M800446-MCP200 PMID: 19196707
38. Ghochikyan A, Petrushina I, Davtyan H, Hovakimyan A, Saing T, et al. (2014) Immunogenicity of epitope vaccines targeting different B cell antigenic determinants of human alpha-synuclein: Feasibility study. Neurosci Lett 560: 86-91. doi: 10.1016/j.neulet.2013.12.028 PMID: 24361548
39. Angela M. Cenci ML (2005) Utility of 6-Hydroxydopamine Lesioned Rats in the Preclinical Screening of Novel Treatments for Parkinson Disease; LeDoux, editor: Elsevier Science. 193-208 p. PMID: 25275211
40. Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST (2000) CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39: 777-787. PMID: 10699444
41. Iancu R, Mohapel P, Brundin P, Paul G (2005) Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav Brain Res 162: 1-10. PMID: 15922062
42. Kirik D, Georgievska B, Burger C, Winkler C, Muzyczka N, et al. (2002) Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer. Proc Natl Acad Sci U S A 99: 4708-4713. PMID: 11917105
43. Alerte TN, Akinfolarin AA, Friedrich EE, Mader SA, Hong CS, et al. (2008) Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice. Neurosci Lett 435: 24-29. doi: 10.1016/j.neulet.2008.02.014 PMID: 18314273
44. Gorbatyuk OS, Li S, Sullivan LF, Chen W, Kondrikova G, et al. (2008) The phosphorylation state of Ser- 129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc Natl Acad Sci U S A 105: 763-768. doi: 10.1073/pnas.0711053105 PMID: 18178617
45. Decressac M, Mattsson B, Lundblad M, Weikop P, Bjorklund A (2012) Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons. Neurobiol Dis 45: 939-953. doi: 10.1016/j.nbd.2011.12.013 PMID: 22182688
46. Pabon MM, Jernberg JN, Morganti J, Contreras J, Hudson CE, et al. (2012) A spirulina-enhanced diet provides neuroprotection in an alpha-synuclein model of Parkinson's disease. PLoS One 7: e45256. doi: 10.1371/journal.pone.0045256 PMID: 23028885
47. Bartels T, Ahlstrom LS, Leftin A, Kamp F, Haass C, et al. (2010) The N-terminus of the intrinsically disordered protein alpha-synuclein triggers membrane binding and helix folding. Biophys J 99: 2116-2124. doi: 10.1016/j.bpj.2010.06.035 PMID: 20923645
48. Vamvaca K, Volles MJ, Lansbury PT Jr. (2009) The first N-terminal amino acids of alpha-synuclein are essential for alpha-helical structure formation in vitro and membrane binding in yeast. J Mol Biol 389: 413-424. doi: 10.1016/j.jmb.2009.03.021 PMID: 19285989
49. Kortekaas R, Leenders KL, van Oostrom JC, Vaalburg W, Bart J, et al. (2005) Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 57: 176-179. PMID: 15668963
50. Zhang Y, Lee DH (2011) Sink hypothesis and therapeutic strategies for attenuating Abeta levels. Neuroscientist 17: 163-173. doi: 10.1177/1073858410381532 PMID: 21330304
51. Harms AS, Cao S, Rowse AL, Thome AD, Li X, et al. (2013) MHCII is required for alpha-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J Neurosci 33: 9592-9600. doi: 10.1523/JNEUROSCI.5610-12.2013 PMID: 23739956
52. Guo JL, Lee VM (2014) Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat Med 20: 130-138. doi: 10.1038/nm.3457 PMID: 24504409
53. Valera E, Masliah E (2013) Immunotherapy for neurodegenerative diseases: focus on alpha-synucleinopathies. Pharmacol Ther 138: 311-322. doi: 10.1016/j.pharmthera.2013.01.013 PMID: 23384597
54. Lemere CA (2013) Immunotherapy for Alzheimer's disease: hoops and hurdles. Mol Neurodegener 8: 36. doi: 10.1186/1750-1326-8-36 PMID: 24148220
55. Yu YJ, Watts RJ (2013) Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics 10: 459-472. doi: 10.1007/s13311-013-0187-4 PMID: 23549647
56. Liu L, Li Y (2014) The unexpected side effects and safety of therapeutic monoclonal antibodies. Drugs Today (Barc) 50: 33-50. doi: 10.1358/dot.2014.50.1.2076506 PMID: 24524104